LexisPSL
Crucial Development on the Presumption of Confidentiality in the Access to Document Saga (PTC Therapeutics v EMA and MSD Animal Health Innovation, Intervet v EMA)
September 19, 2019
The saga of access to documents (ATD) cases in the European pharmaceutical legal landscape continues, this time with two promising opinions of Advocate-General Hogan. In summary AG Hogan found that the General Court had erred in law in its conclusions that (a) there was no general presumption of confidentiality and (b) access to the study reports submitted in a marketing authorisation application dossier at issue would not compromise the applicants’ commercial interests.
This article has been originally published on LexisPSL.
Contacts

Capabilities
Suggested News & Insights
Sidley Healthcare Investment Conference 2026Tuesday, September 22, 2026Swiss MedTech 2026Tuesday, August 25, 2026Sidley Adds Life Sciences Transactions Partner Jiqiang (JQ) Lin in New YorkAugust 12, 2026Shifting Expectations: FDA Takes a First Step Toward Making GRAS Notifications MandatoryAugust 12, 2026Managing IP Recognizes Sidley and 12 Lawyers in IP Stars 2026July 31, 2026When AI Changes the Deal: Rethinking Risk, Milestones, and Timing in Life Sciences M&AJuly 29, 2026
- Stay Up To DateSubscribe to Sidley Publications
- Follow Sidley on Social MediaSocial Media Directory
